Recent studies evaluated CgA as a valuable biomarker in various stressful diseases including neuroendocrine tumors (Di Giacinto et al., 2018), cardiovascular disorders (Ottesen et al., 2017; Mahata et al., 2018), atopic dermatitis (Cai et al., 2018), ulcerative colitis (Magnusson et al., 2018) and diabetes mellitus (Herold et al., 2018). The gene discussed is CGA; the disease is neuroendocrine neoplasm.